Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $2,314,121.74 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 78,127 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74. Following the transaction, the chief executive officer now owns 109,956 shares in the company, valued at $3,256,896.72. This trade represents a 41.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44.
• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.33, for a total transaction of $747,375.11.

Hims & Hers Health Stock Performance

Shares of HIMS stock traded down $0.13 during mid-day trading on Tuesday, hitting $31.12. 14,635,490 shares of the stock were exchanged, compared to its average volume of 9,946,161. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The stock has a market capitalization of $6.80 billion, a price-to-earnings ratio of 70.09 and a beta of 1.25. The stock's fifty day simple moving average is $25.02 and its two-hundred day simple moving average is $21.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) earnings per share. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the period. State Street Corp grew its holdings in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after buying an additional 206,078 shares during the last quarter. Geode Capital Management LLC increased its position in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after acquiring an additional 482,177 shares during the period. Wellington Management Group LLP raised its stake in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock worth $30,714,000 after acquiring an additional 218,566 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. TD Cowen reiterated a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price for the company. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Finally, Piper Sandler reissued a "neutral" rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and a consensus target price of $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.